Chronic Kidney Diseases, Healthy
Conditions
Keywords
Salt blood test, endothelial glycocalyx, chronic kidney disease, syndecan-1, heparan sulfate
Brief summary
The luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (EG). EG is important for the transport of molecules in and out of the blood cells and for endothelial function. EG protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. Overall it is likely to avoid development of cardiovascular disease. A newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of EG. EG can also be measured by release of endothelial glycocalyx proteins. Previous studies indicate that this EG is impaired by a number of chronic diseases, including chronic kidney disease. This study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.
Detailed description
The purpose of this study is to gain knowledge about how pronounced the EG are affected in varying degrees of chronic kidney disease compared with healthy controls assessed by 1. salt-blood test 2. release of endothelial glycocalyx proteins. and to see how this correlates to 1. blood pressure (peripheral and central) 2. pulse wave velocity 3. albuminuria 4. coagulation system 5. vasoactive hormones (PRC, p-Ang-II, p-Aldo, p-ANP, p-BNP, p-AVP)
Interventions
None listed
Sponsors
Regional Hospital Holstebro
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
patients with chronic kidney disease: CKD I-V Age\> 18 years 4 diabetics in each CKD-class Dialysis patients must have received dialysis for at least 3 months. Signed consent
Exclusion criteria
, patients with chronic kidney disease: Nephrotic syndrome (U-alb\> 3.5 g / d, p-alb \<30 g / l, and peripheral edema) Alcohol abuse Drug abuse Pregnancy and lactation Hbg \<6.2 mmol / l Inclusion criteria, healthy people: Both gender Signed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Erythrocyte Salt Sensitivity | 1 minute | Blood sample |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heparan Sulfate | 1 minute | blood sample |
| blood pressure central and peripheral | 1 minute | Mobil-O-Graph |
| Vasoactive hormones (PRC, Ang-II, Aldo, ANP, BNP, AVP) | 1 minute | blood samples |
| Syndecan-1 | 1 minute | blood sample |
| Albuminuria | 1 minute | urine sample |
| coagulation | 1 minute | blood samples |
| pulse wave velocity | 1 minute | Mobil-O-Graph |
Outcome results
None listed